We conclude that transcriptional upregulation of COX-2 and subsequent PGE2 release following CTX-treatment is a key determinant of the cellular and molecular features underpinning the inflammatory response induced by dying cancer cells in vivo. This evidence concerns the gene PTGS2 and cancer.